Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants

Enviar para

Título:
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants
Autor: Shah, Prakeshkumar S ; Jasani, Bonny ; Mitra, Souvik ; Shah, Prakeshkumar S
Assuntos: Acetaminophen ; Acetaminophen - adverse effects ; Cardiovascular Disorders ; Child health ; Congenital heart disease ; Drug Therapy, Combination ; Drug Therapy, Combination - adverse effects ; Ductus Arteriosus, Patent ; Ductus Arteriosus, Patent - drug therapy ; Genetic disorders ; Heart & circulation ; Humans ; Ibuprofen ; Ibuprofen - therapeutic use ; Indomethacin ; Indomethacin - therapeutic use ; Infant ; Infant, Low Birth Weight ; Infant, Newborn ; Infant, Premature ; Medicine General & Introductory Medical Sciences ; Neonatal care ; Patent Ductus Arteriosus ; Randomized Controlled Trials as Topic
É parte de: Cochrane database of systematic reviews, 2022-12, Vol.2022 (12), p.CD010061
Notas: new_version
Descrição: Background The different management strategies for patent ductus arteriosus (PDA) in preterm infants are expectant management, surgery, or medical treatment with non‐selective cyclo‐oxygenase inhibitors. Randomized controlled trials (RCTs) have suggested that paracetamol may be an effective and safe agent for the closure of a PDA. Objectives To determine the efficacy and safety of paracetamol as monotherapy or as part of combination therapy via any route of administration, compared with placebo, no intervention, or another prostaglandin inhibitor, for prophylaxis or treatment of an echocardiographically‐diagnosed PDA in preterm or low birth weight infants. Search methods We searched CENTRAL, MEDLINE, Embase, and three trials registers on 13 October 2021, and one other database on 1 March 2022. We also checked references and contacted study authors to identify additional studies. Selection criteria We included RCTs and quasi‐RCTs in which paracetamol (single‐agent or combination therapy) was compared to no intervention, placebo, or other agents used for closure of PDA, irrespective of dose, duration, and mode of administration in preterm infants. Two independent authors reviewed the search results and made a final selection of potentially eligible articles through discussion. Data collection and analysis We performed data collection and analyses in accordance with the methods of Cochrane Neonatal. We used the GRADE approach to assess the certainty of evidence for the following outcomes: failure of ductal closure after the first course of treatment; all‐cause mortality during initial hospital stay; and necrotizing enterocolitis (NEC). Main results For this update, we included 27 studies enrolling 2278 infants. We considered the overall risk of bias in the 27 studies to vary from low to unclear. We identified 24 ongoing studies. Paracetamol versus ibuprofen There was probably little to no difference between paracetamol and ibuprofen for failure of ductal closure after the first course (risk ratio (RR) 1.02, 95% confidence interval (CI) 0.88 to 1.18; 18 studies, 1535 infants; moderate‐certainty evidence). There was likely little to no difference between paracetamol and ibuprofen for all‐cause mortality during hospital stay (RR 1.09, 95% CI 0.80 to 1.48; 8 studies, 734 infants; moderate‐certainty evidence), and for NEC (RR 1.30, 95% CI 0.87 to 1.94; 10 studies, 1015 infants; moderate‐certainty evidence). Paracetamol versus indomethacin There was little to no difference between paracetamol and indomethacin for failure of ductal closure after the first course (RR 1.02, 95% CI 0.78 to 1.33; 4 studies, 380 infants; low‐certainty evidence). There was little to no difference between paracetamol and indomethacin for all‐cause mortality during hospital stay (RR 0.86, 95% CI 0.39 to 1.92; 2 studies, 114 infants; low‐certainty evidence). The rate of NEC may be lower in the paracetamol group (3.7%) versus the indomethacin group(9.2%) (RR 0.42, 95% CI 0.19 to 0.96; 4 studies, 384 infants; low‐certainty evidence). Prophylactic paracetamol versus placebo/no intervention Prophylactic paracetamol (17%) compared to placebo/no intervention (61%) may reduce failure of ductal closure after one course (RR 0.27, 95% CI 0.18 to 0.42; 3 studies, 240 infants; low‐certainty evidence). There was little to no difference between prophylactic paracetamol and placebo/no intervention for all‐cause mortality during hospital stay (RR 0.59, 95% CI 0.24 to 1.44; 3 studies, 240 infants; low‐certainty evidence). No studies reported on NEC. Early paracetamol treatment versus placebo/no intervention Early paracetamol treatment (28%) compared to placebo/no intervention (79%) may reduce failure of ductal closure after one course when used before 14 days' postnatal age (RR 0.35, 95% CI 0.23 to 0.53; 2 studies, 127 infants; low‐certainty evidence). No studies reported on all‐cause mortality during hospital stay or NEC. Late paracetamol treatment versus placebo/no intervention There was little to no difference between late paracetamol and placebo for failure of ductal closure after one course of treatment when used at or after 14 days' postnatal age (RR 0.85, 95% CI 0.72 to 1.01; 1 study, 55 infants; low‐certainty evidence) or NEC (RR 1.04, 95% CI 0.07 to 15.76; 1 study, 55 infants; low‐certainty evidence). No data were reported for all‐cause mortality during hospital stay. Paracetamol combined with ibuprofen versus ibuprofen combined with placebo or no intervention There was little to no difference between paracetamol plus ibuprofen compared to ibuprofen plus placebo or no intervention for failure of ductal closure after the first course (RR 0.77, 95% CI 0.43 to 1.36; 2 studies, 111 infants; low‐certainty evidence). There was little to no difference between paracetamol plus ibuprofen compared to ibuprofen plus placebo or no intervention for NEC (RR 0.33, 95% CI 0.01 to 7.45; 1 study, 24 infants; low‐certainty evidence). No data were reported for all‐cause mortality during hospital stay. Authors' conclusions Moderate‐certainty evidence suggests that there is probably little or no difference in effectiveness between paracetamol and ibuprofen; low‐certainty evidence suggests that there is probably little or no difference in effectiveness between paracetamol and indomethacin; low‐certainty evidence suggests that prophylactic paracetamol may be more effective than placebo/no intervention; low‐certainty evidence suggests that early paracetamol treatment may be more effective than placebo/no intervention; low‐certainty evidence suggests that there is probably little or no difference between late paracetamol treatment and placebo, and probably little or no difference in effectiveness between the combination of paracetamol plus ibuprofen versus ibuprofen alone for the closure of PDA after the first course of treatment. The majority of neonates included in these studies were of moderate preterm gestation. Thus, establishing the efficacy and safety of paracetamol for PDA treatment in extremely low birth weight (ELBW: birth weight < 1000 grams) and extremely low gestational age neonates (ELGANs < 28 weeks' gestation) requires further studies.
Editor: Chichester, UK: John Wiley & Sons, Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants

Shah, Prakeshkumar S ; Jasani, Bonny ; Mitra, Souvik ; Shah, Prakeshkumar S

Chichester, UK: John Wiley & Sons, Ltd

Buscando em bases de dados remotas. Favor aguardar.